Ista CEO Vince Anido: An Interview With “The Pink Sheet” DAILY (Part 2 of 2)
This article was originally published in The Pink Sheet Daily
Executive Summary
Exec discusses mid-stage pipeline, recent deal with Tanabe Seiyaku for bepotastine and the market for nasal allergy products - and Ista as a possible acquisition target.
You may also be interested in...
Ista CEO Vince Anido: An Interview With “The Pink Sheet” DAILY (Part 1 of 2)
Exec discusses firm’s late-stage ophthalmic pipeline, and how his firm can successfully compete against industry heavyweights such as Alcon and Bausch & Lomb.
Ista Gains North American Rights To Bepotastine For Nasal Allergies From Tanabe Seiyaku
H1 receptor antagonist will enter clinic for nasal indication in late 2008/early 2009, firm tells “The Pink Sheet” DAILY.
Actelion CEO Jean-Paul Clozel: An Interview With “The Pink Sheet” DAILY (Part 2 of 2)
CEO Clozel discusses the firm’s renin inhibitor program in the face of Novartis’ Tekturna, alliances with Merck and Roche and its business strategy going forward.